Brokerages Set JAN (NYSE:JAN) Price Target at $31.71

Posted by George Bondi on Sep 18th, 2026

JAN (NYSE:JAN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $32.4375.

A number of research analysts recently issued reports on JAN shares. Huntington initiated coverage on JAN in a research report on Thursday, September 10th. They set an “outperform” rating and a $36.00 price objective for the company. Morgan Stanley upped their price target on shares of JAN from $28.00 to $31.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 18th. Wall Street Zen raised shares of JAN from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. KeyCorp raised their price target on shares of JAN from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, June 10th. Finally, UBS Group set a $29.00 price target on JAN in a report on Thursday, June 18th.

Read Our Latest Analysis on JAN

More JAN News

Here are the key news stories impacting JAN this week:

Positive Sentiment: Upsized credit facility improves liquidity. Janus Living closed an increase in its unsecured revolving credit facility from $600 million to $1.25 billion. The additional borrowing capacity could support acquisitions, development and other capital needs, while replacing the prior $100 million delayed-draw term loan. Janus Living Announces Closing of Upsized $1.25 Billion Revolving Credit Facility
Positive Sentiment: Analysts raised their valuation outlook. Scotiabank increased its price target to $33 from $31 and maintained a “sector outperform” rating. Jefferies initiated coverage with a “buy” rating and a $36 target, while Compass Point began coverage with a “neutral” rating and a $37 target. The targets suggest analysts see further upside from recent trading levels.
Neutral Sentiment: Financing provides flexibility but increases leverage exposure. The larger revolver gives Janus Living more financial flexibility, but investors will likely monitor borrowing costs, debt levels and whether management can deploy the capital into investments that generate attractive returns.
Negative Sentiment: Recent operating results remain a concern. Janus Living’s latest quarterly report showed earnings of $0.05 per share, below the $0.23 consensus estimate, even though revenue exceeded expectations and rose 45.4% year over year. The earnings miss may be weighing on the stock more than the new financing and analyst targets are supporting it.

Hedge Funds Weigh In On JAN

A number of institutional investors and hedge funds have recently bought and sold shares of JAN. WINTON GROUP Ltd acquired a new stake in shares of JAN in the 2nd quarter worth approximately $2,985,000. Engineers Gate Manager LP acquired a new position in shares of JAN during the 2nd quarter valued at $15,274,000. Greenland Capital Management LP bought a new stake in shares of JAN in the 2nd quarter worth $575,000. Readystate Asset Management LP acquired a new stake in shares of JAN in the second quarter valued at $1,724,000. Finally, Wellington Management Group LLP acquired a new stake in JAN in the 2nd quarter valued at about $8,739,000. Institutional investors own 6.27% of the company’s stock.

JAN Stock Down 1.2%

Shares of NYSE JAN opened at $30.20 on Friday. JAN has a twelve month low of $22.76 and a twelve month high of $32.83. The firm has a 50 day moving average price of $30.50.

JAN (NYSE:JAN – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The firm had revenue of $216.46 million for the quarter, compared to the consensus estimate of $203.32 million. The business’s quarterly revenue was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. On average, equities analysts forecast that JAN will post 0.97 EPS for the current year.

JAN Dividend Announcement

The firm also recently declared a monthly dividend, which will be paid on Tuesday, December 29th. Stockholders of record on Friday, December 18th will be paid a $0.0475 dividend. The ex-dividend date of this dividend is Friday, December 18th. This represents a c) annualized dividend and a dividend yield of 1.9%.

About JAN

(Get Free Report)

JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.

JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.

The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.